MR-Spectroscopy: Investigating neurochemical changes in brain metabolism in migraineurs before and after CGRP-Antibody treatment – a randomized, controlled, open-label trial

Background Imaging techniques have revealed important aspects of the underlying pathophysiological mechanisms of migraine, suggesting abnormal energy metabolism and increased cerebral hyperexcitability as triggers for a migraine attack. Since only a small percentage of monoclonal CGRP antibodies crosses the blood-brain barrier, their main site of action outside the blood-brain barrier is discussed. It is uncertain whether they lead to central effects through their action outside the blood-brain barrier or exert direct central effects.